Anti-Diabetes Drugs - Ethiopia

Ethiopia

The Anti-Diabetes Drugs market in Ethiopia is anticipated to witness a significant surge in revenue, with projections indicating a staggering figure of US$71.04m in 2024.
This growth is expected to continue at a steady pace, with an annual growth rate (CAGR 2024-2029) of 8.60%.
As a consequence, the market volume is projected to reach an impressive US$107.30m by 2029.
In the global context, United States is expected to dominate the market, generating the highest revenue of US$37,840.00m in 2024.
Ethiopia is experiencing a growing demand for anti-diabetes drugs, driven by the increasing prevalence of diabetes in the country.

Key regions: India, Australia, Italy, Europe, Brazil

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Diabetes Drugs market in Ethiopia has been experiencing growth in recent years.

Customer preferences: As the prevalence of diabetes continues to rise in Ethiopia, there is a growing demand for anti-diabetes drugs. Patients are increasingly seeking medications that are effective, affordable, and accessible. Additionally, there is a preference for drugs that have fewer side effects and are easier to administer.

Trends in the market: One of the major trends in the Anti-Diabetes Drugs market in Ethiopia is the increasing availability of generic drugs. This has made treatment more affordable for patients who may not be able to afford brand-name medications. Another trend is the growing interest in traditional medicine as a complementary treatment for diabetes. Many patients are turning to herbal remedies and other alternative therapies to manage their condition.

Local special circumstances: Ethiopia is one of the poorest countries in the world, and this has had a significant impact on the Anti-Diabetes Drugs market. Many patients are unable to afford the high cost of medication, and as a result, they may not receive the treatment they need. Additionally, there is a lack of healthcare infrastructure in rural areas, which makes it difficult for patients to access medication and medical care.

Underlying macroeconomic factors: The Ethiopian economy has been growing in recent years, but it remains largely agrarian and underdeveloped. This has limited the resources available for healthcare investment and development. The government has made efforts to improve healthcare access and affordability, but progress has been slow. As a result, the Anti-Diabetes Drugs market in Ethiopia is likely to continue to face challenges in the coming years.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.